Iron Sequestration and Anemia of Inflammation

Seminars in Hematology

Volumn 46, Issue 4, 2009, Pages 387-393

  Ganz, Tomas ^a   Nemeth, Elizabeta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; ERYTHROPOIETIN; FERRITIN; FERROPORTIN; HEMOGLOBIN; HEMOJUVELIN; HEPCIDIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; IRON; PROTEIN INHIBITOR; TRANSFERRIN;

ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BACTERIAL INFECTION; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; ENDOCYTOSIS; ERYTHROPOIESIS; HEMOGLOBIN SYNTHESIS; HORMONE SYNTHESIS; HUMAN; HYPOPROTEINEMIA; INFLAMMATION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; MACROPHAGE; MICROCYTIC ANEMIA; MYCOSIS; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; VIRUS INFECTION;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; ENTEROCYTES; ERYTHROPOIESIS; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; IRON; MACROPHAGES;

EID: 70349325941     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.06.001     Document Type: Article

References (79)

1. Cartwright G.E., Lauritsen M.A., Jones P.J., Merrill I.M., and Wintrobe M.M. The anemia of infection. I. Hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J Clin Invest 25 (1946) 65-80
2. Cartwright G.E., Lauritsen M.A., Humphreys S., Jones P.J., Merrill I.M., and Wintrobe M.M. The anemia of infection. II. The experimental production of hypoferremia and anemia in dogs. J Clin Invest 25 (1946) 81-86
3. Kemna E., Pickkers P., Nemeth E., van der H.H., and Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106 (2005) 1864-1866
4. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
5. Holbein B.E. Iron-controlled infection with Neisseria meningitidis in mice. Infect Immun 29 (1980) 886-891
6. Beaumier D.L., Caldwell M.A., and Holbein B.E. Inflammation triggers hypoferremia and de novo synthesis of serum transferrin and ceruloplasmin in mice. Infect Immun 46 (1984) 489-494
7. Bertini R., Bianchi M., Erroi A., Villa P., and Ghezzi P. Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron. J Leukoc Biol 46 (1989) 254-262
8. Schaible U.E., Collins H.L., Priem F., and Kaufmann S.H. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 196 (2002) 1507-1513
9. Holbein B.E. Enhancement of Neisseria meningitidis infection in mice by addition of iron bound to transferrin. Infect Immun 34 (1981) 120-125
10. NOYES W.D., Bothwell T.H., and Finch C.A. The role of the reticulo-endothelial cell in iron metabolism. Br J Haematol 6 (1960) 43-55
11. Fillet G., Cook J.D., and Finch C.A. Storage iron kinetics. VII. A biologic model for reticuloendothelial iron transport. J Clin Invest 53 (1974) 1527-1533
12. Cartwright G.E. The anemia of chronic disorders. Semin Hematol 3 (1966) 351-375
13. Corwin H.L., and Krantz S.B. Anemia of the critically ill: "acute" anemia of chronic disease. Crit Care Med 28 (2000) 3098-3099
14. Maccio A., Madeddu C., Massa D., Mudu M.C., Lusso M.R., Gramignano G., et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106 (2005) 362-367
15. Ludwig H., Pohl G., and Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol 2 (2004) 233-241
16. Hastka J., Lasserre J.J., Schwarzbeck A., Strauch M., and Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. Blood 81 (1993) 1200-1204
17. Taylor J.E., Peat N., Porter C., and Morgan A.G. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083
18. Goodnough L.T., Skikne B., and Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 96 (2000) 823
19. Auerbach M., Ballard H., Trout J.R., McIlwain M., Ackerman A., Bahrain H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
20. Kapoian T., O'Mara N.B., Singh A.K., Moran J., Rizkala A.R., Geronemus R., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
21. Coyne D.W., Kapoian T., Suki W., Singh A.K., Moran J.E., Dahl N.V., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol 18 (2007) 975-984
22. Delaby C., Pilard N., Puy H., and Canonne-Hergaux F. Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochem J 411 (2008) 123-131
23. Ashby D.R., Gale D.P., Busbridge M., Murphy K.G., Duncan N.D., Cairns T.D., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75 (2009) 976-981
24. Hume R., Currie W.J., and Tennant M. Anaemia of rheumatoid arthritis and iron therapy. Ann Rheum Dis 24 (1965) 451-457
25. Beamish M.R., Davies A.G., Eakins J.D., Jacobs A., and Trevett D. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 21 (1971) 617-622
26. Auerbach M., Ballard H., and Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 369 (2007) 1502-1504
27. Bishu K., and Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1 (2006) S19-S23
28. Sengoelge G., Sunder-Plassmann G., and Horl W.H. Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr 15 (2005) 105-110
29. Sullivan J.L. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 232 (2007) 1014-1020
30. Corradini E., Ferrara F., Pollicino T., Vegetti A., Abbati G.L., Losi L., et al. Disease progression and liver cancer in the ferroportin disease. Gut 56 (2007) 1030-1032
31. Deugnier Y. Iron and liver cancer. Alcohol 30 (2003) 145-150
32. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
33. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., and Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106 (2005) 2196-2199
34. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 98 (2001) 8780-8785
35. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33 (2003) 21-22
36. Nicolas G., Bennoun M., Porteu A., Mativet S., Beaumont C., Grandchamp B., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 99 (2002) 4596-4601
37. Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., and Andrews N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100 (2002) 3776-3781
38. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
39. Abboud S., and Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275 (2000) 19906-19912
40. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403 (2000) 776-781
41. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5 (2000) 299-309
42. Donovan A., Lima C.A., Pinkus J.L., Pinkus G.S., Zon L.I., Robine S., et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1 (2005) 191-200
43. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 32 (2004) 131-138
44. Melis M.A., Cau M., Congiu R., Sole G., Barella S., Cao A., et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 93 (2008) 1473-1479
45. Rivera S., Liu L., Nemeth E., Gabayan V., Sorensen O.E., and Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 105 (2005) 1797-1802
46. Roy C.N., Mak H.H., Akpan I., Losyev G., Zurakowski D., and Andrews N.C. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109 (2007) 4038-4044
47. Elliott J., Mishler D., and Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 16 (2009) 94-100
48. Sasu B, Hainu M, Boone TC, Bi XJ, Lee KJ, Arvedson T, et al. Hepcidin, hepcidin antagonists and methods of use. Amgen Inc. Patent 12/022,515. 2009. USA. 1-30-2008.
49. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110 (2002) 1037-1044
50. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
51. Wrighting D.M., and Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 108 (2006) 3204-3209
52. Pietrangelo A., Dierssen U., Valli L., Garuti C., Rump A., Corradini E., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132 (2007) 294-300
53. Verga Falzacappa M.V., Vujic S.M., Kessler R., Stolte J., Hentze M.W., and Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109 (2007) 353-358
54. Vinzio S., Ciarloni L., Schlienger J.L., Rohr S., Mechine A., and Goichot B. Isolated microcytic anemia disclosing a unicentric Castleman disease: the interleukin-6/hepcidin pathway?. Eur J Intern Med 19 (2008) 367-369
55. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharmaceut Bull 30 (2007) 2001-2006
56. Brandt S.J., Bodine D.M., Dunbar C.E., and Nienhuis A.W. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86 (1990) 592-599
57. Katsume A., Saito H., Yamada Y., Yorozu K., Ueda O., Akamatsu K., et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20 (2002) 304-311
58. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005) 2627-2632
59. Kawabata H., Tomosugi N., Kanda J., Tanaka Y., Yoshizaki K., and Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92 (2007) 857-858
60. Sharma S., Nemeth E., Chen Y.H., Goodnough J., Huston A., Roodman G.D., et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14 (2008) 3262-3267
61. Cazzola M., Ponchio L., de Benedetti F., Ravelli A., Rosti V., Beguin Y., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87 (1996) 4824-4830
62. Huang F.W., Babitt J.L., Wrighting D.M., Samad T.A., Xia Y., Sidis Y., et al. Hemojuvelin acts as a bone morphogenetic protein co-receptor to regulate hepcidin expression [abstract]. ASH Annual Meeting Abstracts 106 (2005) 511
63. Xia Y., Babitt J.L., Sidis Y., Chung R.T., and Lin H.Y. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 111 (2008) 5195-5204
64. Truksa J., Peng H., Lee P., and Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci 103 (2006) 10289-10293
65. Lin L., Valore E.V., Nemeth E., Goodnough J.B., Gabayan V., and Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 110 (2007) 2182-2189
66. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., and Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117 (2007) 1933-1939
67. Wang R.H., Li C., Xu X., Zheng Y., Xiao C., Zerfas P., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2 (2005) 399-409
68. Andriopoulos J.B., Corradini E., Xia Y., Faasse S.A., Chen S., Grgurevic L., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41 (2009) 482-487
69. Meynard D., Kautz L., Darnaud V., Canonne-Hergaux F., Coppin H., and Roth M.P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41 (2009) 478-481
70. Papanikolaou G., Samuels M.E., Ludwig E.H., MacDonald M.L., Franchini P.L., Dube M.P., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004) 77-82
71. Huang F.W., Pinkus J.L., Pinkus G.S., Fleming M.D., and Andrews N.C. A mouse model of juvenile hemochromatosis. J Clin Invest 115 (2005) 2187-2191
72. Niederkofler V., Salie R., and Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 115 (2005) 2180-2186
73. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006) 531-539
74. Krijt J., Vokurka M., Chang K.T., and Necas E. Expression of Rgmc, the murine ortholog of hemojuvelin gene, is modulated by development and inflammation, but not by iron status or erythropoietin. Blood 104 (2004) 4308-4310
75. Constante M., Wang D., Raymond V.A., Bilodeau M., and Santos M.M. Repression of repulsive guidance molecule C during inflammation is independent of Hfe and involves tumor necrosis factor-alpha. Am J Pathol 170 (2007) 497-504
76. Yang F., Liu X.B., Quinones M., Melby P.C., Ghio A., and Haile D.J. Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 277 (2002) 39786-39791
77. Mueller S., Pantopoulos K., Hubner C.A., Stremmel W., and Hentze M.W. IRP1 activation by extracellular oxidative stress in the perfused rat liver. J Biol Chem 276 (2001) 23192-23196
78. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
79. Ganz T., Olbina G., Girelli D., Nemeth E., and Westerman M. Immunoassay for human serum hepcidin. Blood 112 (2008) 4292-4297